• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Low risk localized prostate cancer: no harm from waiting!

0
  • by alexperjescuadmin
  • in Oncology
  • — 24 Mar, 2013
Andrew Loblaw
Low risk localized prostate cancer: no harm from waiting!
AudioMedica News
Low risk localized prostate cancer: no harm from waiting!
Low risk localized prostate cancer: no harm from waiting!
00:00 /
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-2176"/>

ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Symposium by Dr Andrew Loblaw from the Sunnybrook Health Sciences Centre in Toronto who talked with Peter Goodwin about his group’s finding that the rate of “migration” of Gleason grade — representing the gradual progression of the disease — was gradual, with no more than a third of patients developing a form of the disease requiring treatment within ten years: so the remaining patients can be spared side effects from treatment.



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/130310AndrewLoblawAJOPODCASTLoRes.mp3]

Share

You may also like...

  • Zoran Gatalica Cancers of unknown primary site: biomarker profiling prompts paradigm shift in treatment decision-making 18 Oct, 2013
  • Lana Kandalaft Two-step immunotherapy brings promise in advanced ovarian cancer 8 Apr, 2013
  • Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib 15 Oct, 2018
  • ASCO Audio Journal of Oncology in Advance – February 1st, 2007 – reporting from American Society of Hematology 48th Annual Meeting, December 9-12, 2006 Orlando ASCO Audio Journal of Oncology in Advance – February 1st, 2007 – reporting from American Society of Hematology 48th Annual Meeting, December 9-12, 2006 Orlando 3 Feb, 2007

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Androgen blockade: 18 as good as 36 months in radiotherapy-treated prostate cancer
  • Next story Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Microbiome Diversity Key To Survival After…
    • Breast Cancer: Combined Risk Assessment Prompts…
    • Test Spares Extended Endocrine Therapy In Low-Risk…
  • Home
  • Oncology
  • Low risk localized prostate cancer: no harm from waiting!

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.